The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 7, 2015, Pages 1083-1089

  Meneghel, Lauro ^a   Ruffatti, Amelia ^a   Gavasso, Sabrina ^a   Tonello, Marta ^a   Mattia, Elena ^a   Spiezia, Luca ^a   Campello, Elena ^a   Hoxha, Ariela ^a   Fedrigo, Marny ^a   Punzi, Leonardo ^a   Simioni, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

anti cardiolipin (aCL) antibodies; anti phospholipid antibodies (aPL); anti phospholipid syndrome (APS); anti 2 glycoprotein I (anti 2GPI) antibodies; chemiluminescence immunoassay (CLIA); enzyme linked immunosorbent assay (ELISA)

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; BETA2 GLYCOPROTEIN 1;

ADULT; AGED; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; ADOLESCENT; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; IMMUNOASSAY; IMMUNOLOGY; LUMINESCENCE; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84930801033     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0925     Document Type: Article

References (36)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Conti F, Capozzi A, Truglia S, Lococo E, Longo A, Misasi R, et al. The mosaic of "seronegative" antiphospholipid syndrome. J Immunol Res 2014;2014:1-7.
3. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003;62:1127.
4. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737-40.
5. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. British Committee for Standards in Haematology Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58.
6. Clinical and Laboratory Standards Institute (CLSI). Laboratory testing for the lupus anticoagulant; approved Guideline. CLSI document H60-A. Wayne, PA: CLSI, 2014.
7. Favaloro EJ, Wong RC. Antiphospholipid antibody testing for the antiphospholipid syndrome: a synopsis of challenges and recent guidelines. Pathology 2014;46:481-95.
8. Favaloro EJ, Plebani M, Lippi G. Standardization and harmonization of antiphospholipid antibody assays. Semin Thromb Hemost 2014;40:161-2.
9. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-b2-glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004;2:1860-2.
10. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004;114:553-8.
11. Wong RC, Gillis D, Adelstein S, Baumgart K, Favaloro EJ, Hendle MJ, et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004;36:63-8.
12. Wong RC, Favaloro EJ, Adelstein S, Baumgart K, Bird R, Brighton TA, et al. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. Pathology 2008;40:58-63.
13. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002;11:269-75.
14. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International consensus guidelines on anticardiolipin and anti-2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012;64:1-10.
15. Pierangeli SS, Favaloro EJ, Lakos G, Meroni PL, Tincani A, Wong RC. Standards and reference materials for the anticardiolipin and anti-2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Act 2012;413:358-60.
16. Pierangeli SS, Harris EN. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is Semin Thromb Hemost 2008;34:313-28.
17. Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream Semin Thromb Hemost 2008;34:340-6.
18. Wong R, Favaloro E, Pollock W, Wilson R, Hendle M, Adelstein S. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology 2004;36:182-92.
19. Zhao L, Sun L, Chu X. Chemiluminescence immunoassay. Trends Analyt Chem 2009;28:404-14.
20. Roda A, Guardigli M. Analytical chemiluminescence and bioluminescence: latest achievements and new horizons. Anal Bioanal Chem 2012;402:69-76.
21. Baeyens WR, Schulman SG, Calokerinos AC, Zhao Y, Garcia Campana AM, Nakashima K, et al. Chemiluminescence-based detection: principles and analytical applications in flowing streams and in immunoassays. J Pharm Biomed Anal 1998;17:941-53.
22. Andreoli L, Rizzini S, Allegri F, Meroni P, Tincani A. Are the current attempts at standardization of antiphospholipid antibodies still useful Emerging technologies signal a shift in direction. Semin Thromb Hemost 2008;34:356-60.
23. De Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost 2010;8:1540-6.
24. Persijn L, Decavele AS, Schouwers S, Devreese K. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2011;128:565-9.
25. Van Hoecke F, Persijn L, Decavele AS, Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol 2012;34:630-40.
26. Capozzi A, Lococo E, Grasso M, Longo A, Garofalo T, Misasi R, et al. Detection of antiphospholipid antibodies by automated chemiluminescence assay. J Immunol Methods 2012;379:48-52.
27. Forastiero R, Papalardo E, Watkins M, Nguyen H, Quirbach C, Jaskal K, et al. Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 2014;428:99-105.
28. Mondejar R, Gonzalez-Rodriguez C, Toyos-Saenz de Miera FJ, Melguizo-Madrid E, Zohoury N, Mahler M. Role of antiphospholipid score and anti-2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014;431:174-8.
29. Chung Y, Kim JE, Lim HS, Kim HK. Clinical performance of anticardiolipin and anti2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods. Blood Coagul Fibrinolysis 2014;25:10-5.
30. Ichikawa K, Tsutsumi A, Atsumi T, Matsuura E, Kobayashi S, Hughes GR, et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 1999;42:2461-70.
31. Ruffatti A, Olivieri S, Tonello M, Bortolati M, Bison E, Salvan E, et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008;6:1693-6.
32. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360-3.
33. Fontana P, Poncet A, Lindhoff-Last E, de Moerloose P, Devreese KM. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2-glycoprotein-1 antibodies. J Thromb Haemost 2014;12:2034-7.
34. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
35. Galli M, Reber G, De Moerloose P, De Groot PG. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008;6:399-401.
36. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.